COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab
COSMIC-313 is designed to answer an essential question of whether adding cabozantinib to dual checkpoint inhibition can improve outcomes, specifically in the untreated first-line poor- and intermediate-risk renal cell carcinoma patient population.
The COSMIC-313 study met its primary endpoint, demonstrating a significant progression-free survival benefit in patients receiving the triplet combination. In this MEDtalk, Toni Choueiri, Dana-Farber Cancer Institute, Boston, USA, gives his perspective on the results and the clinical impacts.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.